Evidence map›Paper›PMID 39713073›Full record

ReviewWorld journal of experimental medicine2024

Intravitreal therapy for the management of diabetic retinopathy: A concise review.

Atul Arora, Arvind K Morya, Parul C Gupta, Nitin K Menia, Prateek Nishant, Vishali Gupta

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of experimental medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Evaluating the efficacy and safety of brolucizumab versus aflibercept on visual and anatomical outcomes in diabetic macular edema: a retrospective comparative study.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Atul AroraTeleophthalmology, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, Punjab, India.
Arvind K MoryaDepartment of Ophthalmology, All India Institute of Medical Sciences, Hyderabad 508126, Telangana, India. bulbul.morya@gmail.com.
Parul C GuptaDepartment of Ophthalmology, Post Graduate Institute of Medical Education & Research, Chandigarh 160012, Punjab, India.
Nitin K MeniaDepartment of Ophthalmology, All India Institute of Medical Sciences, Vijaypur 180001, Jammu and Kashmīr, India.
Prateek NishantDepartment of Ophthalmology, ESIC Medical College, Patna 801103, Bihār, India.
Vishali GuptaDepartment of Ophthalmology, Post Graduate Institute of Medical Education & Research, Chandigarh 160012, Punjab, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetic retinopathy (DR) is a serious microvascular complication of diabetes mellitus and may result in irreversible visual loss. Laser treatment has been the gold standard treatment for diabetic macular edema and proliferative diabetic retinopathy for many years. Of late, intravitreal therapy has emerged as a cornerstone in the management of DR. Among the diverse pharmacotherapeutic options, anti-vascular endothelial growth factor agents have demonstrated remarkable efficacy by attenuating neovascularization and reducing macular edema, thus preserving visual acuity in DR patients.

Indexed as

Anti-vascular endothelial growth factorDiabetic retinopathyIntravitreal therapyMacular edemaProliferative diabetic-retinopathy

Identifiers

PMID39713073
PMCPMC11551706

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.